SUMMARY, EXPLANATION AND LIMITATIONS:
CD34 recognizes a single chain transmembrane glycoprotein of 110 kDa. This antigen is selectively expressed in human lymphoid and myeloid hematopoietic progenitor cells. The antibody to CD34 also reacts with vascular endothelial cells in normal tissues, and in benign and malignant proliferations. The utility of CD34 has value in the studies of benign and malignant vascular tumors as well as characterization of acute leukemia in bone marrow. CD34 has been used to measure angiogenesis in many types of tumors, which reportedly predicts tumor recurrence. It is also used to differentiate dermatofibrosarcoma protuberans from fibrous histiocytoma.
Immunogen: Vesicular suspension prepared from human term placenta.
Staining pattern: Cell surface and cytoplasmic.
Positive control: Tissue sample from placenta.
This antibody is designed for the specific localization of human CD34 using IHC techniques in formalin-fixed, paraffin-embedded tissue sections.
This antibody labels the vascular endothelium. It is useful in the diagnosis of vascular tumors with superior performance that the von Willebrand factor and Ulex agglutinin Europeus 1.